June 01, 2020
Lieff Cabraser Heimann & Bernstein LLP and a former firm associate have won $40 million in fees from a $120 million deal they helped hospitals, health insurers and uninsured consumers ink with Sandoz and Momenta over the price of generic blood thinners.
December 11, 2019
Momenta has agreed to pay $35 million to exit a class action brought by a group of drug buyers accusing the company and Sandoz of conspiring to monopolize the blood clot drug Lovenox and its generic version.
October 22, 2019
A Tennessee federal judge refused Monday to pause a lawsuit that accuses Momenta and Sandoz of conspiring to monopolize the blood-clot drug Lovenox and its generic version while they appeal the certification of a class of thousands of drug buyers, prompting the companies to seek emergency Sixth Circuit intervention Tuesday.
October 03, 2019
Momenta and Sandoz have urged a Tennessee federal judge to pause a lawsuit accusing them of conspiring to monopolize blood-clot drug Lovenox and its generic version while they appeal the certification of a class of thousands of drug buyers.
September 20, 2019
A Tennessee federal judge on Friday certified a class of thousands of Lovenox buyers in a suit from a Nashville hospital and a union health plan accusing Momenta and Sandoz of conspiring to monopolize the blood clot drug and its generic version.
September 16, 2019
Momenta and Sandoz have urged a Tennessee federal court to sanction a hospital accusing them of conspiring to monopolize the blood clot drug Lovenox and its generic version for allegedly not properly preserving certain billing records, a move the hospital called a distraction.
May 16, 2019
Nashville's general hospital has one week to amend a proposed class of Lovenox buyers after a Tennessee federal judge rejected a last-minute tweak to the class definition in a lawsuit accusing Momenta and Sandoz of conspiring to monopolize the blood clot drug and its generic version.
December 06, 2018
A Tennessee federal judge has freed Momenta Pharmaceuticals Inc. and Sandoz Inc. from Sherman Act allegations that they conspired to monopolize the market for the blood clot drug Lovenox and its generic version, but kept related state claims alive.
November 19, 2018
Indirect purchasers of blood clot drug Lovenox and its generic version asked a Tennessee federal court for class certification in their suit alleging Momenta Pharmaceuticals Inc. and Sandoz Inc. conspired to monopolize the market for the medication.
February 16, 2018
A Tennessee hospital urged a federal court Thursday to keep its antitrust lawsuit against Momenta Pharmaceuticals Inc. and Sandoz Inc. alive because a related challenge to a Momenta patent is ongoing.